| [1] |
Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84.DOI: 10.1002/hep.28431.
|
| [2] |
Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398.DOI: 10.1016/S2468-1253(19)30039-1.
|
| [3] |
Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69(4): 896-904.DOI: 10.1016/j.jhep.2018.05.036.
|
| [4] |
Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.DOI: 10.1001/jamaoncol.2017.3055.
|
| [5] |
Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10): 589-604.DOI: 10.1038/s41575-019-0186-y.
|
| [6] |
Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2019, 5(12): 1749-1768.DOI: 10.1001/jamaoncol.2019.2996.
|
| [7] |
Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(4): 223-238.DOI: 10.1038/s41575-020-00381-6.
|
| [8] |
Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133.DOI: 10.1002/hep.30702.
|
| [9] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.DOI: 10.3322/caac.21492.
|
| [10] |
Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009[J]. Hepatology, 2015, 62(6): 1723-1730.DOI: 10.1002/hep.28123.
|
| [11] |
Piscaglia F, Svegliati-Baroni G, Barchetti A, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study[J]. Hepatology, 2016, 63(3): 827-838.DOI: 10.1002/hep.28368.
|
| [12] |
Phipps M, Livanos A, Guo A, et al. Gender matters: characteristics of hepatocellular carcinoma in women from a large, multicenter study in the United States[J]. Am J Gastroenterol, 2020, 115(9): 1486-1495.DOI: 10.14309/ajg.0000000000000643.
|
| [13] |
Stine JG, Wentworth BJ, Zimmet A, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases[J]. Aliment Pharmacol Ther, 2018, 48(7): 696-703.DOI: 10.1111/apt.14937.
|
| [14] |
Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review[J]. World J Hepatol, 2019, 11(1): 1-18.DOI: 10.4254/wjh.v11.i1.1.
|
| [15] |
Hagström H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1. 2 million men[J]. Gut, 2018, 67(8): 1536-1542.DOI: 10.1136/gutjnl-2016-313622.
|
| [16] |
Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts[J]. BMC Med, 2019, 17(1): 95.DOI: 10.1186/s12916-019-1321-x.
|
| [17] |
Raff EJ, Kakati D, Bloomer JR, et al. Diabetes mellitus predicts occurrence of cirrhosis and hepatocellular cancer in alcoholic liver and non-alcoholic fatty liver diseases[J]. J Clin Transl Hepatol, 2015, 3(1): 9-16.DOI: 10.14218/JCTH.2015.00001.
|
| [18] |
Yang JD, Ahmed F, Mara KC, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 907-916.DOI: 10.1002/hep.30858.
|
| [19] |
Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J]. Hepatology, 2020, 71(3): 808-819.DOI: 10.1002/hep.31014.
|
| [20] |
Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis[J]. PLoS Med, 2014, 11(4): e1001624.DOI: 10.1371/journal.pmed.1001624.
|
| [21] |
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases[J]. Hepatology, 2018, 68(2): 723-750.DOI: 10.1002/hep.29913.
|
| [22] |
Galle PR, Forner A, Llovet JM, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.DOI: 10.1016/j.jhep.2018.03.019.
|
| [23] |
Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis[J]. Gastroenterology, 2018, 154(6): 1706-1718. e1.DOI: 10.1053/j.gastro.2018.01.064.
|
| [24] |
Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2017, 45(1): 169-177.DOI: 10.1111/apt.13841.
|
| [25] |
Jin L, Min L, Sung L, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis[J]. Radiology, 2015, 275(1): 97-109.DOI: 10.1148/radiol.14140690.
|
| [26] |
Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Hepatology, 2018, 67(1): 401-421.DOI: 10.1002/hep.29487.
|
| [27] |
Terzi E, Ayuso C, Piscaglia F, et al. Liver imaging reporting and data system: review of pros and cons[J]. Semin Liver Dis, 2022, 42(1): 104-111.DOI: 10.1055/s-0041-1732356.
|
| [28] |
Vogel A, Cervantes A, Chau I, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2018, 29(Suppl 4): iv238-iv255.DOI: 10.1093/annonc/mdy308.
|
| [29] |
Calderaro J, Ziol M, Paradis V, et al. Molecular and histological correlations in liver cancer[J]. J Hepatol, 2019, 71(3): 616-630.DOI: 10.1016/j.jhep.2019.06.001.
|
| [30] |
Torbenson MS. Hepatocellular carcinoma: making sense of morphological heterogeneity, growth patterns, and subtypes[J]. Hum Pathol, 2021, 112: 86-101.DOI: 10.1016/j.humpath.2020.12.009.
|
| [31] |
Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients[J]. Clin Gastroenterol Hepatol, 2016, 14(6): 875-886. e6.DOI: 10.1016/j.cgh.2015.12.042.
|
| [32] |
Parikh ND, Mehta AS, Singal AG, et al. Biomarkers for the early detection of hepatocellular carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(12): 2495-2503.DOI: 10.1158/1055-9965.EPI-20-0005.
|
| [33] |
Guan MC, Zhang SY, Ding Q, et al. The performance of GALAD score for diagnosing hepatocellular carcinoma in patients with chronic liver diseases: a systematic review and meta-analysis[J]. J Clin Med, 2023, 12(3): 949.DOI: 10.3390/jcm12030949.
|
| [34] |
Lehrich BM, Zhang J, Monga SP, et al. Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma[J]. J Hepatol, 2024, 80(3): 515-530.DOI: 10.1016/j.jhep.2023.11.030.
|
| [35] |
Angeli-Pahim I, Chambers A, Duarte S, et al. Current trends in surgical management of hepatocellular carcinoma[J]. Cancers, 2023, 15(22): 5378.DOI: 10.3390/cancers15225378.
|
| [36] |
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022, 77(6): 1598-1606.DOI: 10.1016/j.jhep.2022.08.021.
|
| [37] |
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76(3): 681-693.DOI: 10.1016/j.jhep.2021.11.018.
|
| [38] |
Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma[J]. Gastroenterology, 2005, 129(1): 122-130.DOI: 10.1053/j.gastro.2005.04.009.
|
| [39] |
Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase Ⅲ randomised controlled trial[J]. Gut, 2017, 66(6): 1172-1173.DOI: 10.1136/gutjnl-2016-312629.
|
| [40] |
Xu Z, Hall TL, Vlaisavljevich E, et al. Histotripsy: the first noninvasive, non-ionizing, non-thermal ablation technique based on ultrasound[J]. Int J Hyperthermia, 2021, 38(1): 561-575.DOI: 10.1080/02656736.2021.1905189.
|
| [41] |
Wah TM, Pech M, Thormann M, et al. A multi-centre, single arm, non-randomized, prospective European trial to evaluate the safety and efficacy of the HistoSonics system in the treatment of primary and metastatic liver cancers (#HOPE4LIVER)[J]. Cardiovasc Intervent Radiol, 2023, 46(2): 259-267.DOI: 10.1007/s00270-022-03309-6.
|
| [42] |
Mendiratta-Lala M, Wiggermann P, Pech M, et al. The #HOPE4LIVER single-arm pivotal trial for histotripsy of primary and metastatic liver tumors[J]. Radiology, 2024, 312(3): e233051.DOI: 10.1148/radiol.233051.
|
| [43] |
Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study[J]. Cardiovasc Intervent Radiol, 2010, 33(1): 41-52.DOI: 10.1007/s00270-009-9711-7.
|
| [44] |
Young B, Yoo JJ, Won J, et al. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization[J]. Korean J Intern Med, 2019, 34(6): 1223-1232.DOI: 10.3904/kjim.2018.058.
|
| [45] |
Lau WY, Teoh YL, Win KM, et al. Current role of selective internal radiation with yttrium-90 in liver tumors[J]. Future Oncol, 2016, 12(9): 1193-1204.DOI: 10.2217/fon-2016-0035.
|
| [46] |
Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes[J]. Gastroenterology, 2010, 138(1): 52-64.DOI: 10.1053/j.gastro.2009.09.006.
|
| [47] |
Duran R, Deltenre P, Denys A. RE: Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma[J]. Gastroenterology, 2017, 152(6): 1625-1626.DOI: 10.1053/j.gastro.2016.09.069.
|
| [48] |
Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(13): 3843-3849.DOI: 10.3748/wjg.v21.i13.3843.
|
| [49] |
Muñoz-Martínez S, Iserte G, Sanduzzi-Zamparelli M, et al. Current pharmacological treatment of hepatocellular carcinoma[J]. Curr Opin Pharmacol, 2021, 60: 141-148.DOI: 10.1016/j.coph.2021.07.009.
|
| [50] |
Foerster F, Gairing SJ, Ilyas SI, et al. Emerging immunotherapy for HCC: a guide for hepatologists[J]. Hepatology, 2022, 75(6): 1604-1626.DOI: 10.1002/hep.32447.
|
| [51] |
Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2016, 22(29): 6582-6594.DOI: 10.3748/wjg.v22.i29.6582.
|
| [52] |
Lange NF, Radu P, Dufour JF. Prevention of NAFLD-associated HCC: role of lifestyle and chemoprevention[J]. J Hepatol, 2021, 75(5): 1217-1227.DOI: 10.1016/j.jhep.2021.07.025.
|
| [53] |
Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis[J]. Hepatology, 2010, 51(1): 121-129.DOI: 10.1002/hep.23276.
|
| [54] |
Lazo M, Solga SF, Horska A, et al. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes[J]. Diabetes Care, 2010, 33(10): 2156-2163.DOI: 10.2337/dc10-0856.
|
| [55] |
Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis[J]. Gastroenterology, 2015, 149(2): 367-378. e5; quiz e14-e15.DOI: 10.1053/j.gastro.2015.04.005.
|
| [56] |
Tamura T, Wada K, Konishi K, et al. Coffee, green tea, and caffeine intake and liver cancer risk: a prospective cohort study[J]. Nutr Cancer, 2018, 70(8): 1210-1216.DOI: 10.1080/01635581.2018.1512638.
|
| [57] |
Longo M, Meroni M, Paolini E, et al. Mitochondrial dynamics and nonalcoholic fatty liver disease (NAFLD): new perspectives for a fairy-tale ending?[J]. Metabolism, 2021, 117: 154708.DOI: 10.1016/j.metabol.2021.154708.
|
| [58] |
Petrick JL, Campbell PT, Koshiol J, et al. Tobacco, alcohol use and risk of hepatocellular carcinoma and intrahepatic cholangiocarcinoma: the Liver Cancer Pooling Project[J]. Br J Cancer, 2018, 118(7): 1005-1012.DOI: 10.1038/s41416-018-0007-z.
|
| [59] |
El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence[J]. Clin Gastroenterol Hepatol, 2006, 4(3): 369-380.DOI: 10.1016/j.cgh.2005.12.007.
|
| [60] |
Papadakos SP, Ferraro D, Carbone G, et al. The emerging role of metformin in the treatment of hepatocellular carcinoma: is there any value in repurposing metformin for HCC immunotherapy?[J]. Cancers, 2023, 15(12): 3161.DOI: 10.3390/cancers15123161.
|
| [61] |
Harati R, Vandamme M, Blanchet B, et al. Drug-drug interaction between metformin and sorafenib alters antitumor effect in hepatocellular carcinoma cells[J]. Mol Pharmacol, 2021, 100(1): 32-45.DOI: 10.1124/molpharm.120.000223.
|
| [62] |
Simon TG, Duberg AS, Aleman S, et al. Association of aspirin with hepatocellular carcinoma and liver-related mortality[J]. N Engl J Med, 2020, 382(11): 1018-1028.DOI: 10.1056/NEJMoa1912035.
|
| [63] |
Simon TG, Henson J, Osganian S, et al. Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2019, 17(13): 2776-2784. e4.DOI: 10.1016/j.cgh.2019.04.061.
|
| [64] |
Foderà D, D’Alessandro N, Cusimano A, et al. Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors[J]. Ann N Y Acad Sci, 2004, 1028: 440-449.DOI: 10.1196/annals.1322.052.
|